Revenue: $4.25 billion, up 7% organically year-over-year. Adjusted EBITDA: $601 million, up 23% year-over-year. Adjusted EBITDA Margin: 14.2%, increased by 190 basis points. Non-GAAP Net Income: $391 million. Non-GAAP Diluted EPS: $2.97, up 30% year-over-year. National Security and Digital Revenues: Increased 5% year-over-year. Health & Civil Revenues: Increased 8% year-over-year. Commercial & International Revenues: Increased 12% year-over-year. Defense Systems Revenues: Increased 7% year-over-year. Cash Flow from Operating Activities: $58 million. Free Cash Flow: $36 million. Debt: $5.1 billion, with a gross leverage ratio of 2.3x. Cash and Cash Equivalents: $842 million at quarter end. Backlog: $46.3 billion, up about $3 billion from last quarter. Full-Year 2025 Revenue Guidance: $16.9 billion to $17.3 billion. Full-Year 2025 Adjusted EBITDA Guidance: Mid- to high 12% range. Full-Year 2025 Non-GAAP Diluted EPS Guidance: $10.35 to $10.75. Full-Year 2025 Operating Cash Flow Guidance: Approximately $1.45 billion. Warning! GuruFocus has detected 5 Warning Signs with SEDG. Release Date: May 06, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Leidos Holdings Inc (NYSE:LDOS) reported a strong Q1 2025 with organic revenue growth of 7% year-over-year. Adjusted EBITDA margins improved to 14.2%, and non-GAAP diluted earnings per share rose by 30%. The company reaffirmed its full-year 2025 guidance, indicating confidence in its strategic direction. Leidos Holdings Inc (NYSE:LDOS) executed a $500 million accelerated share repurchase agreement, demonstrating strong capital allocation. The company announced a definitive agreement to acquire a leader in full-spectrum cyber, enhancing its NorthStar 2030 strategic growth pillars. Negative Points The Health & Civil segment saw a decline, with no large single-award IDIQs benefiting from backlog adjustments. The first quarter included an extra week of payroll, impacting cash flow performance. Leidos Holdings Inc (NYSE:LDOS) faces potential revenue impacts from the new administration's initiatives, although currently estimated to be negligible. The company is navigating a volatile macro environment, which could impact future bookings and revenue growth. There is uncertainty regarding the potential impact of continued resolutions and budget constraints on future opportunities. Q & A Highlights Q: How are things going with the NGEN contract and the current contracting environment, especially with some Navy leadership canceling peers' software contracts? A: Thomas Bell, CEO: The impact on our revenue from macro actions by the administration is negligible, in the very low 1% range. We're seeing opportunities, particularly with DISA and the Defense Enclave services, and are excited about the additional acquisitions and modernizations in the DoD. Story Continues Q: Can you provide more color on the Health & Civil segment, which was the only one that saw a decline? A: Christopher Cage, CFO: The Health & Civil segment recently won the big VBA recompete. While there aren't many large single-award IDIQs in this area, we have pending opportunities like the MHS Genesis follow-on and the Reserve Health Readiness program. The segment is well-funded and has ample capacity to support its trajectory. Q: What is Leidos' involvement with the GSA request regarding potential contract offerings? A: Thomas Bell, CEO: We engaged actively with the GSA to help make the government smarter and more efficient. We've been involved in discussions and meetings, positioning ourselves as part of the solution. Our mission-critical work is key to customer outcomes, and we're focusing on making government services better, faster, and cheaper. Q: How is Leidos positioned regarding the VA EHR modernization work, given the recent budget funding? A: Thomas Bell, CEO: Managed health services is a growth pillar for us. We're optimistic about growing our health business, with increasing volumes in VBA and health benefits exams. We're also a strong partner with Oracle on the military health side, and we see opportunities to expand our offerings into the VA's EHR rollout. Q: Can you discuss the potential impact of the supplemental defense bill on Leidos, particularly in missile defense and the maritime domain? A: Thomas Bell, CEO: The reconciliation bill represents upside for Leidos, with FAA modernization and border security being key areas. We're also well-positioned for the Golden Dome initiative, with various programs and solutions that can contribute to the architecture needed to secure the U.S. The maritime domain is another area of excitement, with record demand for our unmanned capabilities. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. View Comments
Leidos Holdings Inc (LDOS) Q1 2025 Earnings Call Highlights: Strong Growth and Strategic ...
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...